In the BioHarmony Drug Report Database

"Preview" Icon

Dabigatran

Pradaxa (dabigatran) is a small molecule pharmaceutical. Dabigatran was first approved as Pradaxa on 2008-03-17. It has been approved in Europe to treat replacement arthroplasty and venous thromboembolism. The pharmaceutical is active against prothrombin. Pradaxa’s patents are valid until 2031-01-20 (FDA).

 

Trade Name

 

Pradaxa
 

Common Name

 

dabigatran
 

ChEMBL ID

 

CHEMBL48361
 

Indication

 

replacement arthroplasty, venous thromboembolism
 

Drug Class

 

Thrombin inhibitors (argatroban type)

Image (chem structure or protein)

Dabigatran structure rendering